Merck Group, Pfizer and Eli Lilly have, in quick succession, announced that they are considering moves to sell large, non-core parts of their businesses. Intellectual property, and its valuation, would inevitably play a large part in such transactions. But perhaps more significantly, the pressures for consolidation and specialisation which are driving these sales may also spur a new wave of patent-driven pharmaceutical deals in coming years.

Want to read more?

Register to access two of our subscriber-only articles per month

Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts

Already registered? Log in

What our customers are saying

IAM magazine is, in my opinion, the premier magazine in the space of managing intellectual assets for value creation. It brings a fresh, business-driven perspective, rather than a purely legal perspective, on this issue. I would highly recommend it to anyone dealing with how to manage and drive value from intellectual assets.

David A VandenEinde
Assistant vice president and intellectual asset management leader
Cargill Inc


Subscribe to receive access to the full range of premium business intelligence, insights and analysis, as well as our IP directories, guides and daily news.

Why subscribe?